Lupin launches Tolvaptan Tablets in the US with 180-day exclusivity
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Scores highest PAT of Rs. 118 crore in FY25
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Gelhaus has a proven track record of driving business growth
Subscribe To Our Newsletter & Stay Updated